HOME PRODUCTS COMPANY CONTACT FAQ

Research Dictionary Pharma

Sign Up FREE or Login

annamycin

structure given in first source

Also Known As:

2'-iodo-3'-hydroxy-4'-epi-4-demethoxydoxorubicin

Networked: 18 relevant articles (1 outcomes, 4 trials/studies)

Relationship Network

Bio-Agent Context: Research Results

Experts

1.	Anuszewska, Elzbieta L: 4 articles (03/2008 - 05/2005)
2.	Fokt, Izabela: 4 articles (03/2008 - 05/2005)
3.	Gruber, Beata M: 4 articles (03/2008 - 05/2005)
4.	Priebe, Waldemar: 4 articles (05/2007 - 07/2002)
5.	Bubko, Irena: 3 articles (03/2008 - 05/2005)
6.	Goździk, Aneta: 2 articles (05/2007 - 01/2006)
7.	Andreeff, Michael: 1 article (08/2013)
8.	Ford, Laurie A: 1 article (08/2013)
9.	Heffner, Thompson L: 1 article (08/2013)
10.	Kantarjian, Hagop M: 1 article (08/2013)

Related Diseases

1.	Cardiotoxicity 03/01/1999 - "The observation that Adriamycin preferentially accumulates in cardiac-muscle (CM) but not in cardiac non-muscle (NM) cells while Annamycin accumulates equally in both, may explain in part the reduced cardiotoxicity of Annamycin. " 11/01/1995 - "Preclinical toxicity of liposome-incorporated annamycin: selective bone marrow toxicity with lack of cardiotoxicity." 03/01/1999 - "The reduced cardiotoxicity of Annamycin is approximately 10 fold lower than Adriamycin whereas the increased efficacy against the MDR+ Friend leukemia tumor cell line is about 2 fold. "
2.	Leukemia 03/01/1999 - "The reduced cardiotoxicity of Annamycin is approximately 10 fold lower than Adriamycin whereas the increased efficacy against the MDR+ Friend leukemia tumor cell line is about 2 fold. " 03/01/1999 - "Using an in vitro cardiac cell system and MDR+ and MDR- Friend leukemia cell lines we find that a relatively new anthracycline, Annamycin, has reduced cardiotoxic activity but is more effective in inhibiting the growth of MDR+ cells than Adriamycin. " 07/15/1996 - "The novel anthracycline annamycin is not affected by P-glycoprotein-related multidrug resistance: comparison with idarubicin and doxorubicin in HL-60 leukemia cell lines."
3.	Melanoma (Melanoma, Malignant) 03/01/2008 - "The aim of this study was to assess the effects of doxorubicin (DOX) and its analogs (annamycin, WP903) on the NFkappaB activity in human melanoma cells: a sensitive (ME18) and a resistant to DOX (ME18/R) and its possible correlation with cell sensitivity to these drugs. " 05/01/2007 - "Parental human ME18 melanoma cells and the ME18/R subline, obtained experimentally, resistant to doxorubicin (DOX), exposed to 1.7 and 8.6 microM DOX or its analogs, annamycin and WP903 (both 0.3 and 3.0 microM) were studied. " 01/01/2006 - "Stabilization of cleavable complexes by the topoisomerase II inhibitors leading to DNA lesions and next to apoptosis is the most common mechanism of drug resistance reflected in reduced formation of the complexes due to decreased amounts and/or activity of topoisomerase II. The aim of this study was to characterize human melanoma and human cervix carcinoma cells differing in sensitivity to doxorubicin and anthracycline analogs, annamycin and WP903 for topoisomerase IIalpha protein and gene expression with use of Western blot and RT- PCR. "
4.	Carcinoma (Carcinomatosis) 05/01/2005 - "Parental human cervix carcinoma cells, HeLa, and its subline resistant to vinblastine, KB-V1, were exposed to doxorubicin (DOX) and the novel anthracyclines annamycin and WP903, given at the concentrations 0.2 and 2.0 microg/ml (DOX and annamycin) or 0.2 and 1.0 microg/ml (WP903). " 01/01/2006 - "Stabilization of cleavable complexes by the topoisomerase II inhibitors leading to DNA lesions and next to apoptosis is the most common mechanism of drug resistance reflected in reduced formation of the complexes due to decreased amounts and/or activity of topoisomerase II. The aim of this study was to characterize human melanoma and human cervix carcinoma cells differing in sensitivity to doxorubicin and anthracycline analogs, annamycin and WP903 for topoisomerase IIalpha protein and gene expression with use of Western blot and RT- PCR. "
5.	Breast Neoplasms (Breast Cancer) 07/01/2002 - "Phase II study of liposomal annamycin in the treatment of doxorubicin-resistant breast cancer." 01/01/2001 - "The effects of liposome-encapsulated annamycin (L-Ann) were investigated in two human breast cancer cell lines, MCF7 and MDA-MB-435. " 01/01/2001 - "Effects of liposome-entrapped annamycin in human breast cancer cells: interference with cell cycle progression and induction of apoptosis."

Related Drugs and Biologics

1.	Doxorubicin (Adriamycin)
2.	Anthracyclines
3.	Topoisomerase II Inhibitors
4.	Proteins (Proteins, Gene)
5.	Type II DNA Topoisomerases (Topoisomerase II)
6.	Liposomes (Liposome)
7.	Lipids
8.	Multidrug Resistance-Associated Proteins
9.	Member 1 Subfamily B ATP Binding Cassette Transporter
10.	Idarubicin (4 Demethoxydaunorubicin)